

Certificate of Analysis

Product Name: Crizotinib

Catalog No.: 4368


Batch No.: 2

CAS Number: 877399-52-5

IUPAC Name: 3-[(1*R*)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1*H*-pyrazol-4-yl]-2-pyridinamine

1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula: C₂₁H₂₂Cl₂FN₅O
Batch Molecular Weight: 450.34
Physical Appearance: White solid
Solubility: DMSO to 10 mM
ethanol to 10 mM
2eq.HCl to 100 mM
Storage: Store at +4°C
Batch Molecular Structure:



2. ANALYTICAL DATA

HPLC: Shows 99.8% purity
¹H NMR: Consistent with structure
Mass Spectrum: Consistent with structure
Microanalysis:

	Carbon	Hydrogen	Nitrogen
Theoretical	56.01	4.92	15.55
Found	56.01	4.92	15.64

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

Product Name: Crizotinib

Catalog No.: 4368

Batch No.: 2

CAS Number: 877399-52-5

IUPAC Name: 3-[(1*R*)-1-(2,6-Dichloro-3-fluorophenyl)ethoxy]-5-[1-(4-piperidinyl)-1*H*-pyrazol-4-yl]-2-pyridinamine

Description:

Potent inhibitor of c-MET and anaplastic lymphoma kinase (ALK) (cell IC₅₀ values are 8.0 and 20 nM respectively). Displays antitumor efficacy in multiple tumor models; inhibits c-MET-dependent proliferation, migration and invasion of human tumor cells in vitro. Selective for c-MET and ALK against >120 different kinases. Orally bioavailable.

Physical and Chemical Properties:


Batch Molecular Formula: C₂₁H₂₂Cl₂FN₅O

Batch Molecular Weight: 450.34

Physical Appearance: White solid

Minimum Purity: >99%

Batch Molecular Structure:



References:

Christensen et al (2007) Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. *Mol.Cancer Ther.* **6** 3314. PMID: 18089725.

Zou et al (2007) An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. *Cancer Res.* **67** 4408. PMID: 17483355.

Cui et al (2011) Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). *J.Med.Chem.* **54** 6342. PMID: 21812414.

Congratulations on your purchase of Crizotinib, sold under license from Pfizer, Inc. If your research with Crizotinib results in a new discovery (e.g., new uses, new combinations, etc.) Pfizer is interested in discussing these discoveries with you. Also note that Pfizer has a Compound Transfer Program that provides a free sample of any Pfizer product at www.pfizer.com/research/rd_works/compound_transfer_program.jsp

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

bio-techne.com
info@bio-techne.com
techsupport@bio-techne.com

North America
Tel: (800) 343 7475

China
info.cn@bio-techne.com
Tel: +86 (21) 52380373

Europe Middle East Africa
Tel: +44 (0)1235 529449

Rest of World
www.tocris.com/distributors
Tel:+1 612 379 2956